Q-omics provides the consensus-scored RALGDS profile across patient tissues and cancer cell-line models. RALGDS expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RALGDS is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RALGDS RNA expression shows 19,618 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, KIRC, and UVM as cancer lineages where RALGDS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RALGDS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RALGDS survival associations across molecular data types. RALGDS RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RALGDS RNA expression–survival associations across cancer types. High RALGDS expression shows unfavorable associations in COAD, KIRP, THCA and DLBC, but favorable associations in CESC and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RALGDS RNA expression.
This table summarizes RALGDS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RALGDS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RALGDS shows higher tumor expression in KIRC, COAD, CHOL, LIHC, KIRP and STAD. The KIRC box plot shows higher RALGDS RNA expression in tumor versus normal tissue (log2 FC = +1.134, t-test p < 0.001).
This table shows molecular features associated with RALGDS in patient tissues and cancer cell lines. In patient samples, RALGDS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RALGDS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
